Solid Biosciences (SLDB) Equity Ratio: 2017-2024
Historic Equity Ratio for Solid Biosciences (SLDB) over the last 7 years, with Sep 2024 value amounting to 0.79.
- Solid Biosciences' Equity Ratio rose 0.90% to 0.79 in Q3 2024 from the same period last year, while for Sep 2024 it was 0.79, marking a year-over-year increase of 0.90%. This contributed to the annual value of 0.77 for FY2023, which is 5.71% down from last year.
- Per Solid Biosciences' latest filing, its Equity Ratio stood at 0.79 for Q3 2024, which was down 5.75% from 0.84 recorded in Q2 2024.
- In the past 5 years, Solid Biosciences' Equity Ratio registered a high of 0.90 during Q3 2021, and its lowest value of 0.55 during Q3 2020.
- Over the past 3 years, Solid Biosciences' median Equity Ratio value was 0.80 (recorded in 2023), while the average stood at 0.81.
- As far as peak fluctuations go, Solid Biosciences' Equity Ratio crashed by 33.81% in 2020, and later skyrocketed by 63.50% in 2021.
- Solid Biosciences' Equity Ratio (Quarterly) stood at 0.77 in 2020, then grew by 16.11% to 0.90 in 2021, then declined by 9.23% to 0.81 in 2022, then declined by 5.71% to 0.77 in 2023, then increased by 0.90% to 0.79 in 2024.
- Its Equity Ratio stands at 0.79 for Q3 2024, versus 0.84 for Q2 2024 and 0.85 for Q1 2024.